Immunic, Inc. develops novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), focused on multiple sclerosis. Company news commonly covers clinical and scientific presentations, patent protection for vidofludimus calcium, pipeline updates, and corporate communications tied to its late-stage development strategy.
Updates also include governance changes, board and executive appointments, Nasdaq listing compliance, capital actions such as its reverse stock split, and investor conference participation. Immunic's pipeline references additional earlier-stage programs, including IMU-856 and IMU-381, tied to neurodegenerative, chronic inflammatory, and autoimmune-related disease areas.
Immunic, Inc. (Nasdaq: IMUX) has successfully closed a public offering of 5,750,000 shares of common stock at $18.00 per share, raising approximately $103.5 million. This includes the full exercise of the underwriters' option to purchase an additional 750,000 shares. The proceeds will be utilized to advance clinical development for lead candidates IMU-838, IMU-935, and IMU-856, particularly for a potential Phase 3 trial of IMU-838 in relapsing-remitting multiple sclerosis. The offering was managed by SVB Leerink, with Wedbush PacGrow and Ladenburg Thalmann acting as co-managers.
Immunic, Inc. (Nasdaq: IMUX) has announced a public offering of 5,000,000 shares at $18.00 each, aiming to raise approximately $90.0 million. The offering, subject to customary closing conditions, is expected to close on August 7, 2020. The net proceeds will fund the clinical development of key candidates, including IMU-838 for multiple sclerosis. The company has also granted underwriters a 30-day option to purchase an additional 750,000 shares. This offering follows a shelf registration statement with the SEC.
Immunic, Inc. (Nasdaq: IMUX) has announced plans to offer 5 million shares of common stock in an underwritten public offering, with underwriters granted an option for 750,000 additional shares. This is part of their ongoing efforts to support the development of selective oral immunology therapies for chronic inflammatory diseases. The offering's completion is dependent on market conditions. Joint bookrunning managers for this offering are SVB Leerink and Piper Sandler, with additional involvement from Wedbush PacGrow and Ladenburg Thalmann.
Immunic, Inc. (Nasdaq: IMUX) announced it will report its financial results for Q2 2020 on August 3, 2020, prior to U.S. market opening. The company is focused on oral therapies for chronic inflammatory and autoimmune diseases, including its lead product IMU-838, currently in phase 2 trials for multiple conditions, including COVID-19 and relapsing-remitting multiple sclerosis. A public conference call will follow the results announcement at 8:30 a.m. ET on the same day. Investors can access a live webcast or replay on Immunic's website.
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, announced its participation in several investor conferences in August 2020. Management will engage in fireside chats at the BTIG Virtual Biotechnology Conference on August 10 at 3:30 pm ET, the Wedbush PacGrow Healthcare Virtual Conference on August 12 at 1:45 pm ET, and the Canaccord Genuity 40th Annual Growth Conference on August 12 at 11:00 am ET. Live webcasts will be available on the company’s website, with replays accessible for 90 days post-conference.
Immunic, Inc. (Nasdaq: IMUX) announced the enrollment of the first patients in the IONIC trial, a phase 2b clinical study for its oral DHODH inhibitor, IMU-838, targeting COVID-19. The trial aims to assess the efficacy and safety of IMU-838 combined with Oseltamivir in 120 adults with moderate-to-severe cases. IMU-838 has shown promising preclinical activity against SARS-CoV-2 and a favorable safety profile in earlier trials. The study is supported by the UHCW NHS Trust and LifeArc's £10 million initiative to expedite COVID-19 therapeutics.
Immunic, Inc. (Nasdaq: IMUX) announced its inclusion in the Russell 3000 Index effective June 29, 2020, following the annual reconstitution. This milestone reflects Immunic's progress in developing oral therapies for chronic inflammatory and autoimmune diseases, particularly its lead compound, IMU-838, which is undergoing four Phase 2 trials. Inclusion in the Russell 3000 Index enhances visibility and liquidity for the company's stock, with approximately $9 trillion in assets benchmarked against Russell indexes.
Immunic, Inc. (Nasdaq: IMUX) has begun dosing the first patients in its phase 2 CALVID-1 clinical trial for IMU-838, a selective oral DHODH inhibitor, aimed at treating moderate COVID-19. The trial, approved by regulatory bodies in Germany, the U.S., and other European countries, includes 230 hospitalized patients across 10 to 35 centers. Top-line data is expected later this year, with an interim analysis planned after 200 patients. IMU-838 has strong preclinical support and aims to show efficacy, safety, and tolerability, potentially leading to a phase 3 trial depending on interim results.